Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
277 studies found for:    "Glomerulonephritis"
Show Display Options
Rank Status Study
1 Completed Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis
Condition: Primary Glomerulonephritis
Intervention: Drug: pentoxifylline
2 Terminated Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis
Condition: Glomerulonephritis
Interventions: Drug: pentoxifylline;   Drug: corticosteroids
3 Completed Recurrent Glomerulonephritis After Renal Transplantation
Condition: Glomerulonephritis
Intervention:
4 Recruiting ACE-inhibitors in Extracapillary Glomerulonephritis
Condition: Extracapillary Glomerulonephritis
Intervention: Drug: Lisinopril
5 Active, not recruiting Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Condition: Fibrillary Glomerulonephritis
Intervention: Drug: rituximab
6 Completed Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
Condition: IGA Glomerulonephritis
Intervention: Drug: Ramipril or losartan
7 Completed Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
Condition: Glomerulonephritis, Membranoproliferative
Intervention: Drug: Rituximab
8 Not yet recruiting Immunoadsorption in Anti-GBM Glomerulonephritis.
Condition: Anti-glomerular Basement Membrane Glomerulonephritis
Intervention: Device: Immunoadsorption (Immunosorba)
9 Completed Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis
Condition: IGA Glomerulonephritis
Intervention:
10 Recruiting Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
Conditions: Glomerulonephritis;   Proteinuria
Interventions: Drug: Shenyankangfu tablets;   Drug: Losartan potassium 50mg;   Drug: Shenyankangfu tablets and Losartan potassium 50mg;   Drug: Shenyankangfu tablets and Losartan potassium 100mg;   Drug: Losartan potassium 100mg
11 Active, not recruiting Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG)
Condition: Nephrotic Syndrome Secondary to Idiopathic Membranous Glomerulonephritis
Interventions: Drug: tacrolimus;   Drug: tacrolimus and mycophenolate mofetil
12 Active, not recruiting Eculizumab in Primary MPGN
Condition: Membranoproliferative Glomerulonephritis
Intervention: Drug: Eculizumab
13 Completed Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
Conditions: Chronic Glomerulonephritis;   Diabetic Nephropathy
Intervention: Drug: olmesartan medoxomil
14 Completed Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis
Conditions: ADPKD;   Glomerulonephritis
Intervention: Drug: Ng-monomethyl-L-arginine (drug)
15 Unknown  A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
Condition: Glomerulonephritis
Intervention: Drug: Adrenocorticotrophic hormone ACTH
16 Completed Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy
Condition: IGA Glomerulonephritis
Intervention: Device: Holter
17 Completed Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy
Condition: IGA Glomerulonephritis
Intervention: Drug: enalapril
18 Completed Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy
Condition: IGA Glomerulonephritis
Interventions: Drug: omega-3 fatty acids;   Drug: prednisone
19 Completed Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
Condition: Glomerulonephritis
Intervention: Drug: Ramipril
20 Unknown  ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT
Condition: Glomerulonephritis, IGA
Interventions: Drug: prednisone + Inhibace/Cozaar;   Drug: Inhibace/Cozaar

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.